# OnCo record pancreatic-cancer-uk-drug-access (term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/terms/pancreatic-cancer-uk-drug-access/>
  a schema:DefinedTerm ;
  onco:kind "term" ;
  schema:identifier "pancreatic-cancer-uk-drug-access" ;
  schema:name "Pancreatic cancer drugs in England: NICE appraisals and the Cancer Drugs Fund (September 2026)"@en ;
  schema:alternateName "NICE pancreatic cancer"@en, "Pancreatic cancer NHS funding"@en, "Cancer Drugs Fund pancreatic"@en ;
  schema:description "In England the funded pancreatic cancer drugs are the older chemotherapies: FOLFIRINOX, gemcitabine with capecitabine, gemcitabine alone, and nab-paclitaxel with gemcitabine when other combinations are unsuitable. Liposomal irinotecan after gemcitabine was turned down in 2017, the olaparib and NALIRIFOX appraisals ended without a submission, and the 2026 drugs were unappraised."@en ;
  schema:url <https://onco.cc/terms/pancreatic-cancer-uk-drug-access/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://www.nice.org.uk/guidance/ta476>, <https://www.nice.org.uk/guidance/ta440>, <https://www.nice.org.uk/guidance/ng85/chapter/Recommendations>, <https://www.nice.org.uk/guidance/ta25>, <https://www.nice.org.uk/guidance/ta630>, <https://www.nice.org.uk/guidance/terminated/ta750>, <https://www.nice.org.uk/guidance/terminated/ta1052>, <https://www.nice.org.uk/guidance/terminated/ta1118>, <https://www.nice.org.uk/guidance/ta914>, <https://www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancer-hematologic-malignancies-approval-notifications> ;
  onco:cancers <https://onco.cc/cancers/pancreatic/>, <https://onco.cc/cancers/metastatic-pdac/>, <https://onco.cc/cancers/brca-palb2-pdac/>, <https://onco.cc/cancers/kras-wild-type-pdac/>, <https://onco.cc/cancers/msi-high-pdac/> ;
  onco:drugs <https://onco.cc/drugs/gemcitabine/>, <https://onco.cc/drugs/nab-paclitaxel/>, <https://onco.cc/drugs/gemcitabine-nab-paclitaxel/>, <https://onco.cc/drugs/liposomal-irinotecan/>, <https://onco.cc/drugs/nalirifox/>, <https://onco.cc/drugs/folfirinox/>, <https://onco.cc/drugs/capecitabine/>, <https://onco.cc/drugs/olaparib/>, <https://onco.cc/drugs/daraxonrasib/>, <https://onco.cc/drugs/zenocutuzumab/>, <https://onco.cc/drugs/larotrectinib/>, <https://onco.cc/drugs/entrectinib/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/sotorasib/>, <https://onco.cc/drugs/optune/> ;
  onco:institutions <https://onco.cc/institutions/nice/> ;
  onco:terms <https://onco.cc/terms/cancer-drugs-fund/>, <https://onco.cc/terms/accelerated-approval/>, <https://onco.cc/terms/tumour-agnostic/> .